It is not too late for ... percutaneous angiography in a 90-plus population

Abstract Funding Acknowledgements Type of funding sources: None. Introduction Elderly people represent a vulnerable but increasing population presenting to percutaneous coronary intervention (PCI). The benefit revascularization in acute syndromes (ACS) is well-stablished. However, the elderly patients has been questioned, considering patient’s expected survival, functional and cognitive status, comorbidities, procedure’s risk need for extended anti-thrombotic therapy. Purpose To evaluate effect PCI on prognosis group very old with syndrome (ACS). Methods We retrospectively analyzed all consecutive (≥90-year-old) admitted ACS submitted coronarography (CA) one tertiary center, from January 2008 December 2021. Clinical features were collected, including major adverse cardiac events (MACE), defined composite endpoint all-cause death, ischemic stroke, ACS, or hospitalization heart failure, which compared according if was performed not. Q-square, Cox regression Log-rank tests applied. Results A total 79 enrolled; 43 them underwent PCI. Groups comparable basal characteristics, similar median age at event (92 years old, interquartile range IQR: 3), see picture 1. Most ST-elevation (STE) (n=45) had (70% vs. 41%, p= 0,01), while non (NSTE) unstable angina there higher proportion non-PCI (30% 58%, 0,01). Individuals more likely have single double lesion vessel (76% vs 27%, p<001), presented complex disease (23% 25%, p=0,5). Among PCI-patients, majority singly revascularized (86%) stent implantation (83%). Regarding in-hospital mortality, no difference between groups: 21% versus 33% control (p=0.2). During follow-up time 6 months (IQR: 27), mortality both groups (79% 67%; p=0.1). Nevertheless, overall MACE-free survival significantly longer than no-PCI group, treated MACE 52% lower assigned medical therapy (hazard ratio 0.508, p=0.007); 2. Conclusion Very either survival. These finding suggest that may systematically stent. Efforts should be made optimize care this under-represented clinical trials.